THE DUBERSTEIN GROUP INC. for PFIZER INC.
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Deficit reduction efforts - Proposed legislation re this issue.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL BERMAN | — |
| STEVEN CHAMPLIN | — |
| KENNETH DUBERSTEIN | — |
| BRIAN GRIFFIN | — |
| DANIEL P MEYER | — |
| MARTI THOMAS | — |
| ERIC UELAND | — |
Taxation/Internal Revenue Code TAX
Corporate tax reform, including international taxes and tax extenders - Proposed legislation re these issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL BERMAN | — |
| STEVEN CHAMPLIN | — |
| KENNETH DUBERSTEIN | — |
| BRIAN GRIFFIN | — |
| DANIEL P MEYER | — |
| ERIC UELAND | — |
Health Issues HCR
FDA user fee agreements - Proposed legislation re this issue. Incentives to developing antibiotics - HR 2182, Generating Antibiotic Incentives Now Act of 2011; S 1734, Generating Antibiotic Incentives Now Act of 2011. Bulletin on essential benefits - Executive Branch action re this issue. Encourage the discovery and development of new treatments for patients with chronic or rare diseases - HR 3497, MODDERN Cures Act of 2011. Repeal Independent Payment Advisory Board provision of PL 111-148, PL 111-152 - HR 452, Medicare Decisions Accountability Act of 2011; HR 5, Protecting Access to Healthcare Act; S 2118, Health Care Bureaucrats Elimination Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL BERMAN | — |
| STEVEN CHAMPLIN | — |
| KENNETH DUBERSTEIN | — |
| BRIAN GRIFFIN | — |
| DANIEL P MEYER | — |
| MARTI THOMAS | — |
| ERIC UELAND | — |
Medicare/Medicaid MMM
Sustainable growth rate and impact on other Medicare programs, medicare physician payment, budget offsets - HR 3630, Temporary Payroll Tax Cut Continuation Act of 2011.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL BERMAN | — |
| STEVEN CHAMPLIN | — |
| KENNETH DUBERSTEIN | — |
| BRIAN GRIFFIN | — |
| DANIEL P MEYER | — |
| MARTI THOMAS | — |
| ERIC UELAND | — |
Pharmacy PHA
Addressing drug shortages, including enhanced evaluation of companies and manufacturing sites, real-cause analysis, inventory at companies, improving quality control processes - Proposed legislation re these issues. Opiate abuse issues - Proposed legislation re this issue. Tracking and tracing medicines - Proposed legislation re this issue. Antidote for exposure to chemical agents - Executive Branch action re this issue.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL BERMAN | — |
| STEVEN CHAMPLIN | — |
| KENNETH DUBERSTEIN | — |
| BRIAN GRIFFIN | — |
| DANIEL P MEYER | — |
| MARTI THOMAS | — |
| ERIC UELAND | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.